Hirsch-Reinshagen Veronica, Velenosi Adam, Morris Sarah R, Dong Kevin, Samadi-Bahrami Zahra, Nassimbwa Sureyah, Abdelaziz Eslam, Kozlowski Piotr, Moore G R Wayne, Laule Cornelia, Kwon Brian K
Department of Pathology and Laboratory Medicine, University of British Columbia, British Columbia, Canada.
International Collaboration on Repair Discoveries, University of British Columbia, British Columbia, Canada.
J Neurotrauma. 2022 Dec;39(23-24):1708-1715. doi: 10.1089/neu.2022.0175. Epub 2022 Jul 26.
Over the past few decades, tremendous advances have been made in our understanding of the biological changes underpinning the devastating impairment of traumatic spinal cord injury (SCI). Much of this scientific research has focused on animal models of SCI, and comparatively little has been done in human SCI, largely because biospecimens from human SCI patients are not readily available. This paucity of scientific enquiry in human SCI represents an important void in the spectrum of translational research, as biological differences between animal models and the human condition need to be considered in the pre-clinical development of therapeutic approaches. The International Spinal Cord Injury Biobank (ISCIB) is a multi-user biorepository with the mission of accelerating therapeutic development in traumatic SCI through improved biological understanding of human injury, and the vision of serving as a global research resource where human SCI biospecimens are shared with researchers around the world. Aligned with internationally recognized best practices, ISCIB's formal governance structure and standard operating procedures have earned it official biobank certification through the Canadian Tissue Repository Network. Herein, we describe the translational research gap that ISCIB is helping to fill; its structure, governance and certification; how data and samples are accrued, processed and stored; and finally, the process through which samples and data are shared with global researchers. The purpose of this paper describing ISCIB is to serve as an introductory guidance document for the wider community of SCI researchers. By helping researchers understand the contents of ISCIB and the process of accessing biospecimens, we seek to further ISCIB's vision as being a resource for human and translational research in SCI, with the ultimate goal of finding disease-modifying therapies for this disabling condition.
在过去几十年里，我们对创伤性脊髓损伤（SCI）所致严重损害背后的生物学变化的理解取得了巨大进展。这项科学研究大多集中在SCI的动物模型上，而在人类SCI方面所做的工作相对较少，主要是因为人类SCI患者的生物样本不容易获得。人类SCI研究的匮乏代表了转化研究领域的一个重要空白，因为在治疗方法的临床前开发中需要考虑动物模型与人类情况之间的生物学差异。国际脊髓损伤生物样本库（ISCIB）是一个多用户生物样本库，其使命是通过增进对人类损伤的生物学理解来加速创伤性SCI的治疗开发，并致力于成为一个全球性研究资源，与世界各地的研究人员共享人类SCI生物样本。遵循国际认可的最佳实践，ISCIB的正式管理结构和标准操作程序使其通过了加拿大组织样本库网络的官方生物样本库认证。在此，我们描述了ISCIB正在帮助填补的转化研究空白；其结构、管理和认证；数据和样本是如何获取、处理和存储的；最后，样本和数据与全球研究人员共享的过程。本文描述ISCIB的目的是作为一份面向更广泛SCI研究人员群体的入门指导文件。通过帮助研究人员了解ISCIB的内容以及获取生物样本的过程，我们力求进一步实现ISCIB作为SCI人类和转化研究资源的愿景，最终目标是找到针对这种致残病症的疾病修饰疗法。
